| | |
Reuters 04:01 PM | November 11,2009
Patents protection for Roche’s Tamiflu in US and Europe has not allowed Cipla to sell its generic version in these two geographies, its chairman Y K Hamied said
|
|
Sumeet Chatterjee / Reuters 10:54 AM | November 11,2009
Analysts say growth in the sector will also be boosted by the biggest loss of patent protection in history in the next couple of years
|
|
C.H. Unnikrishnan 11:39 PM | October 30,2009
The company’s sales during the period grew 12% at Rs522.68 crore compared with Rs478.84 crore
|
|
C.H. Unnikrishnan 12:16 AM | October 30,2009
Small growth in sales, increased raw material and interest costs, and pricing pressure on some of its key products in the US led to the decline
|
|
C.H. Unnikrishan 12:08 AM | October 30,2009
Sales grew 4.6% from the year-ago period to Rs161.5 crore
|
|
Archi Damania / CNBC-TV18 12:53 AM | October 29,2009
Cipla chairman and managing director Y.K. Hamied said a lot of the growth has been in the anti-AIDS drugs
|
|
C.H. Unnikrishnan 11:31 PM | October 28,2009
Aventis Pharma, an India-listed unit of French drug maker Sanofi-Aventis SA, is locked in a tussle over the vaccine with Novartis Healthcare Ltd, the Indian subsidiary of Switzerland’s Novartis AG
|
|
PTI 03:25 PM | October 27,2009
The company had reported a net profit of Rs10.5 crore in the similar period last year, Fortis Healthcare said in a statement
|
|
Mark to Market | Mobis Philipose and Vatsala Kamat 01:02 AM | October 27,2009
The fall in sales was mainly the result of an all-round dip across developed markets
|
|
C.H. Unnikrishnan 10:57 PM | October 26,2009
Pfizer Inc., the world’s largest drug maker, bought Wyeth in January in a $68 billion (around Rs3.2 trillion) global deal
|
|
Radhieka Pandeya 09:12 PM | October 26,2009
The company has registered a profit despite a 53% decline in sales in the US and a 25% drop in Romania
|
|
C.H. Unnikrishnan 12:19 AM | October 23,2009
It posted a 44.8% rise in net profit to Rs100 crore in the September quarter
|
|
Samar Srivastava 09:49 PM | October 15,2009
John Yoshimura, COO of AT Kearney says firms that had anticipated the recession and slashed costs are more often than not today’s winners
|
|
Mark to Market | Manas chakravarty, Ravi Ananthanarayanan and Vatsala Kamat 01:15 AM | October 12,2009
IMS Health, a global pharmaceutical market research company, has released its latest forecast for 2010, in which it projects the global pharmaceutical market to grow by 4-6%
|
|
Shamnad Basheer 09:33 PM | October 11,2009
Recent alliances such as Ranbaxy-Daiichi, Indian generics firms are now acquiring dual personalities and speaking the language of patents and innovation
|
|